Nanog-mediated stem cell properties are critical for MBNL3-associated paclitaxel resistance of ovarian cancer. (18th February 2021)

• Record Type: Journal Article
• Authors: Sun, Xueqin; Diao, Xinghua; Zhu, Xiaolin; Yin, Xuexue; Cheng, Guangying
• Is Part Of: Journal of biochemistry. Volume 169:Number 6(2021)
• Page Start: 747
• Page End: 756
• Publication Date: 2021-02-18
• Subjects: MBNL3 -- Nanog -- ovarian cancer -- paclitaxel resistance -- stem-like cells; Biochemistry -- Periodicals; Biochemistry -- Periodicals; Electronic journals; 572.05
• DOI: 10.1093/jb/mvab021
• Languages: English
• ISSNs: 0021-924X

Abstract

Abstract: Paclitaxel (PTX) is the standard first-line treatment of ovarian cancer, but its efficacy is limited by multidrug resistance. Therefore, it is crucial to identify effective drug targets to facilitate PTX sensitivity for ovarian cancer treatment. Seventy PTX-administrated ovarian cancer patients were recruited in this study for gene expression and survival rate analyses. Muscleblind-like-3 (MBNL3) gain-of-function and loss-of-function experiments were carried out in ovarian cancer cells (parental and PTX-resistant) and xenograft model. Cancer cell viability, apoptosis, spheroids formation, Nanog gene silencing were examined and conducted to dissect the underlying mechanism of MBNL3-mediated PTX resistance. High expression of MBNL3 was positively correlated with PTX resistance and poor prognosis of ovarian cancer. MBNL3 increased cell viability and decreased apoptosis in ovarian stem-like cells, through upregulating Nanog. This study suggests the MBNL3-Nanog axis is a therapeutic target for the treatment of PTX resistance in ovarian cancer management.